Loading…
Loading…
ZLDPF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for ZLDPF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ZLDPF and 80,000+ other tickers.
See exactly how ZLDPF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ZLDPF and 80,000+ other tickers.
Based in Copenhagen, Denmark, Zealand Pharma A/S operates as a biotechnology company dedicated to the entire lifecycle of peptide-based medicines – from their initial discovery and development through to their ultimate commercialization. Its therapeutic portfolio primarily targets gastrointestinal and metabolic disorders, alongside other specialized conditions where existing treatments are insufficient. Currently, Zealand Pharma offers lixisenatide, marketed as Adlyxin and Lyxumia. They also commercialize Dasiglucagon, available in a single-use syringe or autoinjector format, which addresses…
Zealand Pharma A/S (ZLDPF) came out with quarterly earnings of $8.61 per share, beating the Zacks Consensus Estimate of a loss of $0.42 per share. This compares to earnings of $16.06 per share a year ago.
Recent setbacks for Danish biotech Zealand Pharma forced analysts to rethink the company's obesity strategy While its drug survodutide disappointed in terms of dropout rates, analysts remain upbeat on its amylin-based drug petrelintide
Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine. Drugmakers pitched doctors and investors on their future drugs at the recent American Diabetes Association (ADA) Scientific Sessions in New Orleans.
Nearly a fifth of patients exited the survodutide trial due to adverse gastrointestinal events such as nausea, vomiting and diarrhea, Boehringer said.
Zealand Pharma lost a fifth of its market value on Monday after a late-stage trial found many patients stopped taking a weight-loss drug due to tolerability problems.